Sionna and Odyssey end JPM week with IPO filingsnews2025-01-20T12:46:25+00:00January 20th, 2025|Endpoints News|
Another US biotech emerges with drug candidate from China-based Keymednews2025-01-20T11:48:36+00:00January 20th, 2025|Endpoints News|
JPM’s M&A Monday frenzy; Ozempic selected for IRA negotiations; Pfizer says it’s back on track; and morenews2025-01-18T11:00:23+00:00January 18th, 2025|Endpoints News|
Sage sues Biogen days after $469M buyout offernews2025-01-17T21:12:51+00:00January 17th, 2025|Endpoints News|
FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefitnews2025-01-17T19:46:40+00:00January 17th, 2025|Endpoints News|
What Trump’s CMS can and can’t change with the second round of drug price negotiationsnews2025-01-17T18:17:16+00:00January 17th, 2025|Endpoints News|
WuXi AppTec sells medical device testing unit; Layoffs at Notch Therapeuticsnews2025-01-17T15:54:20+00:00January 17th, 2025|Endpoints News|
Novo claims high-dose Phase 3 Wegovy win but sales impact might be mutednews2025-01-17T15:23:48+00:00January 17th, 2025|Endpoints News|
Ozempic makes list for next Medicare negotiation roundnews2025-01-17T13:05:44+00:00January 17th, 2025|Endpoints News|
AstraZeneca wins BTK race to market in first-line mantle cell lymphomanews2025-01-17T12:02:32+00:00January 17th, 2025|Endpoints News|
